Plasma neuropeptide Y of children with neuroblastoma in relation to stage, age and prognosis, and tissue neuropeptide Y

Dötsch, J.; Christiansen, Holger; Hänze, Jörg; Lampert, F.; Rascher, Wolfgang

doi:10.1016/s0167-0115(98)00067-6

Cited by 24 publications

(35 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the increased plasma concentrations of NPY in patients from this group strongly correlated with poor clinical outcome of the disease (death and relapse) and MYCN amplification (Dotsch et al, 1998;Kogner et al, 1994). Interestingly, in advanced neuroblastomas, the elevated levels of NPY in a patient's plasma did not correlate with its high mRNA levels in the tumor tissue (Cohen et al, 1990;Dotsch et al, 1998). Similarly, based on the data from the Oncogenomics data base, high mRNA levels of NPY in tumor tissues correlated with better survival (Wei et al, 2004).…”

Section: Neuropeptide Y -Neuronal Marker or Growth Factor?mentioning

confidence: 88%

“…However, early attempts to use it as a general diagnostic marker failed due to high variability of the peptide's concentrations. More detailed analyses revealed that release of NPY is elevated in stage 3/4 and stage 4s neuroblastomas, but not in stage 1/2 (Dotsch et al, 1998;Kogner et al, 1994). Also, among patients with advanced disease, the NPY levels were diverse, with many cases comparable to healthy controls.…”

Section: Neuropeptide Y -Neuronal Marker or Growth Factor?mentioning

confidence: 93%

“…Also, among patients with advanced disease, the NPY levels were diverse, with many cases comparable to healthy controls. However, the increased plasma concentrations of NPY in patients from this group strongly correlated with poor clinical outcome of the disease (death and relapse) and MYCN amplification (Dotsch et al, 1998;Kogner et al, 1994). Interestingly, in advanced neuroblastomas, the elevated levels of NPY in a patient's plasma did not correlate with its high mRNA levels in the tumor tissue (Cohen et al, 1990;Dotsch et al, 1998).…”

Section: Neuropeptide Y -Neuronal Marker or Growth Factor?mentioning

confidence: 97%

See 2 more Smart Citations

Sympathetic Neurotransmitters in Neuroblastoma – Between Physiology and Pathology

Czarnecka¹,

Tilan²,

Kitlińska³

2012

Neuroblastoma - Present and Future

View full text Add to dashboard Cite

Section: Neuropeptide Y -Neuronal Marker or Growth Factor?mentioning

confidence: 88%

Section: Neuropeptide Y -Neuronal Marker or Growth Factor?mentioning

confidence: 93%

Section: Neuropeptide Y -Neuronal Marker or Growth Factor?mentioning

confidence: 97%

See 1 more Smart Citation

Sympathetic Neurotransmitters in Neuroblastoma – Between Physiology and Pathology

Czarnecka¹,

Tilan²,

Kitlińska³

2012

Neuroblastoma - Present and Future

View full text Add to dashboard Cite

“…In addition, neuropeptide Y (NPY) and its Y2 receptor (NY2R) were selected as examples of antiangiogenesis targets (Lu et al 2010). The high expression levels of the sympathetic neurotransmitter NPY correlates with MYCN amplification and with poor clinic outcome (Dötsch et al 1998). Furthermore, …”

Section: Proposed Molecular Targets Not Yet Explored In the Clinicmentioning

confidence: 99%

“…Hence, NB patients present high levels of NPY in their plasma. These high NPY levels correlate with MYCN amplification and poor clinical outcome (Dötsch et al 1998). NPY induces NB tumour growth and angiogenesis (Kitlinska et al 2005).…”

Section: S Verissimo Et Al: Novel Neuroblastoma Targetsmentioning

confidence: 99%

Neuroblastoma therapy: what is in the pipeline?

Veríssimo¹,

Molenaar²,

Fitzsimons³

et al. 2011

Endocrine-Related Cancer

View full text Add to dashboard Cite

Despite the expansion of knowledge about neuroblastoma (NB) in recent years, the therapeutic outcome for children with a high-risk NB has not significantly improved. Therefore, more effective therapies are needed. This might be achieved by aiming future efforts at recently proposed but not yet developed targets for NB therapy. In this review, we discuss the recently proposed molecular targets that are in clinical trials and, in particular, those that are not yet explored in the clinic. We focus on the selection of these molecular targets for which promising in vitro and in vivo results have been obtained by silencing/inhibiting them. In addition, these selected targets are involved at least in one of the NB tumorigenic processes: proliferation, anti-apoptosis, angiogenesis and/or metastasis. In particular, we will review a recently proposed target, the microtubule-associated protein (MAP) encoded by doublecortin-like kinase gene (DCLK1). DCLK1-derived MAPs are crucial for proliferation and survival of neuroblasts and are highly expressed not only in NB but also in other tumours such as gliomas. Additionally, we will discuss neuropeptide Y, its Y2 receptor and cathepsin L as examples of targets to decrease angiogenesis and metastasis of NB. Furthermore, we will review the micro-RNAs that have been proposed as therapeutic targets for NB. Detailed investigation of these not yet developed targets as well as exploration of multi-target approaches might be the key to a more effective NB therapy, i.e. increasing specificity, reducing toxicity and avoiding long-term side effects.

show abstract

Gene expression of neuronal nitric oxide synthase and adrenomedullin in human neuroblastoma using real-time PCR

et al. 2000

Self Cite

View full text Add to dashboard Cite

The objective of our study was to assess the gene expression of the antiproliferative systems neuronal nitric oxide synthase (nNOS) and adrenomedullin (AM) in human neuroblastoma. A novel real‐time PCR method was evaluated using neuropeptide Y (NPY) for validation. Glyceraldehyd‐3‐phospate dehydrogenase (GAPDH) and NPY gene expression in neuroblastomas of 50 patients were measured in parallel by competitive quantitative and TaqMan real‐time RT‐PCR. AM and nNOS mRNA were determined by real‐time PCR. Our results showed a linear relationship between competitive quantitative and real‐time RT‐PCR measurements of NPY and GAPDH (r = 0.87 and r = 0.92, respectively). AM and nNOS mRNA was found in all tumor samples. AM/GAPDH mRNA increased with higher differentiation according to Shimada (p = 0.013). There was no relation between MYCN amplification nor with the tumor stage (p = 0.78 and p = 0.30, respectively). AM/GAPDH did not relate to recurrence or death in a 5‐year follow‐up period. Neuronal NOS/GAPDH expression did not relate to any biological or clinical parameter of prognosis or differentiation. Similar results were obtained when the neuronal marker protein gene product 9.5 (PGP9.5) was used to normalize mRNA concentration. In conclusion, TaqMan real‐time PCR appears to be a reliable method to quantify gene expression in neuroblastomas. Adrenomedullin mRNA in neuroblastoma is linked to tumor differentiation but not to prognostic markers. Int. J. Cancer 88:172–175, 2000. © 2000 Wiley‐Liss, Inc.

show abstract

Plasma neuropeptide Y of children with neuroblastoma in relation to stage, age and prognosis, and tissue neuropeptide Y

Cited by 24 publications

References 16 publications

Sympathetic Neurotransmitters in Neuroblastoma – Between Physiology and Pathology

Sympathetic Neurotransmitters in Neuroblastoma – Between Physiology and Pathology

Neuroblastoma therapy: what is in the pipeline?

Gene expression of neuronal nitric oxide synthase and adrenomedullin in human neuroblastoma using real-time PCR

Contact Info

Product

Resources

About